Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy　― A Single-Center Cohort Study of 227 Patients

Background: Cardiac involvement occurs in more than half of the patients with light-chain amyloidosis (AL), but the characteristics, treatment and prognosis of cardiac AL (CAL) are not fully described. Methods and Results: A total of 227 patients with CAL diagnosis between January 2009 and March 201...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation Journal 2019/03/25, Vol.83(4), pp.775-782
Hauptverfasser:	Feng, Jun, Zhang, Congli, Shen, Kaini, Sun, Jian, Fang, Quan, Zhang, Lu, Cao, Xinxin, Zhou, Daobin, Li, Jian, Tian, Zhuang
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents - therapeutic use Blood Pressure Bone Marrow Cells - cytology Bortezomib Bortezomib - therapeutic use Cardiac amyloidosis Cohort Studies Female Heart Diseases - etiology Heart Diseases - therapy Hematopoietic Stem Cell Transplantation - methods Humans Immunoglobulin Light-chain Amyloidosis - complications Immunoglobulin Light-chain Amyloidosis - mortality Immunoglobulin Light-chain Amyloidosis - therapy Light-chain amyloidosis Male Middle Aged Natriuretic Peptide, Brain - blood NT-proBNP Palliative Care Prognosis Survival Analysis Transplantation, Autologous Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!

Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy ― A Single-Center Cohort Study of 227 Patients

Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy　― A Single-Center Cohort Study of 227 Patients